Analyses of sphingosine-1-phosphate in the context of transfusion: how much is in stored blood products and in patient blood?


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
10 2019
Historique:
received: 27 11 2018
revised: 08 07 2019
accepted: 10 07 2019
pubmed: 5 9 2019
medline: 10 6 2020
entrez: 5 9 2019
Statut: ppublish

Résumé

Sphingosine-1-phosphate (S1P) is a bloodborne lipid that regulates vascular tone and endothelial permeability. S1P concentrations are reduced in critically ill patients. As hematopoietic cells produce S1P, this study intends to investigate S1P concentrations in blood products during storage and in patient plasma after blood transfusion. S1P concentrations were measured in 83 red blood cell (RBC) units and 73 platelet concentrates (PCs) before and after storage. In addition, 26 critically ill patients who received one or two RBC units were recruited to measure S1P plasma levels before and three times within 24 hours after transfusion. The highest S1P concentrations were found in fresh PCs. S1P concentrations in PCs are reduced by 60% when stored at room temperature for 4 days, whereas in RBCs S1P concentrations remained stable when stored at 4°C within 35 days. S1P concentrations in PCs and RBCc were 2.5 to 6 times higher compared to patient plasma. Plasma S1P levels in critically ill patients, however, transiently decreased after transfusion of RBCs and recover to pretransfusion values within the following 24 hours. S1P concentrations in blood products are significantly higher compared to human plasma S1P levels, even though plasma S1P levels decreased after RBC transfusion in critically ill patients and reached pretransfusion values within 24 hours.

Sections du résumé

BACKGROUND
Sphingosine-1-phosphate (S1P) is a bloodborne lipid that regulates vascular tone and endothelial permeability. S1P concentrations are reduced in critically ill patients. As hematopoietic cells produce S1P, this study intends to investigate S1P concentrations in blood products during storage and in patient plasma after blood transfusion.
STUDY DESIGN AND METHODS
S1P concentrations were measured in 83 red blood cell (RBC) units and 73 platelet concentrates (PCs) before and after storage. In addition, 26 critically ill patients who received one or two RBC units were recruited to measure S1P plasma levels before and three times within 24 hours after transfusion.
RESULTS
The highest S1P concentrations were found in fresh PCs. S1P concentrations in PCs are reduced by 60% when stored at room temperature for 4 days, whereas in RBCs S1P concentrations remained stable when stored at 4°C within 35 days. S1P concentrations in PCs and RBCc were 2.5 to 6 times higher compared to patient plasma. Plasma S1P levels in critically ill patients, however, transiently decreased after transfusion of RBCs and recover to pretransfusion values within the following 24 hours.
CONCLUSION
S1P concentrations in blood products are significantly higher compared to human plasma S1P levels, even though plasma S1P levels decreased after RBC transfusion in critically ill patients and reached pretransfusion values within 24 hours.

Identifiants

pubmed: 31483505
doi: 10.1111/trf.15494
doi:

Substances chimiques

Lysophospholipids 0
sphingosine 1-phosphate 26993-30-6
Sphingosine NGZ37HRE42

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3071-3076

Informations de copyright

© 2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.

Références

Winkler MS, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care 2015;19:372-79.
Moritz E, Wegner D, Gross S, et al. Reference intervals for serum sphingosine-1-phosphate in the population-based Study of Health in Pomerania. Clin Chim Acta 2017;468:25-31.
Winkler MS, Nierhaus A, Poppe A, et al. Sphingosine-1-phosphate: a potential biomarker and therapeutic target for endothelial dysfunction and sepsis? Shock 2017;47:666-72.
Wu X, Hou J, Li H, et al. Inverse correlation between plasma sphingosine-1-phosphate and ceramide concentrations in septic patients and their utility in predicting mortality. Shock 2019;51:718-24.
Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202-9.
Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective Sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 2011;108:9613-8.
Jonnalagadda D, Sunkara M, Morris AJ, et al. Granule-mediated release of Sphingosine-1-phosphate by activated platelets. Biochim Biophys Acta 2014;1841:1581-9.
Ulrych T, Bohm A, Polzin A, et al. Release of Sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011;9:790-8.
Cohen B, Matot I. Aged erythrocytes: a fine wine or sour grapes? Br J Anaesth 2013;111(Suppl 1):i62-70.
Ohto H, Nollet KE. Overview on platelet preservation: better controls over storage lesion. Transfus Apher Sci 2011;44:321-5.
Cata JP, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth 2013;110:690-701.
Lovelock JE. The haemolysis of human red blood-cells by freezing and thawing. Biochim Biophys Acta 1953;10:414-26.
McVerry BJ, Peng X, Hassoun PM, et al. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004;170:987-93.
Peng X, Hassoun PM, Sammani S, et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004;169:1245-51.
Selim S, Sunkara M, Salous AK, et al. Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci 2011;121:565-72.
Quintero M, Nunez M, Mellado S, et al. Evaluation of store lesion in platelet obtained by apheresis compared to platelet derived from whole blood and its impact on the in vitro functionality. Transfus Apher Sci 2015;53:293-9.
Black A, Orso E, Kelsch R, et al. Analysis of platelet-derived extracellular vesicles in plateletpheresis concentrates: a multicenter study. Transfusion 2017;57:1459-69.
Ito K, Anada Y, Tani M, et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun 2007;357:212-7.
Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of Sphingosine-1-phosphate. Science 2007;316:295-8.
Bode C, Sensken SC, Peest U, et al. Erythrocytes serve as a reservoir for cellular and extracellular Sphingosine 1-phosphate. J Cell Biochem 2010;109:1232-43.
Thuy AV, Reimann CM, Hemdan NY, et al. Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem 2014;34:158-71.
Weske S, Vaidya M, Reese A, et al. Targeting Sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med 2018;24:667-78.

Auteurs

Annika Poppe (A)

Clinic and Policlinic for Anesthesiology and Intensive Care Medicine, University Medicine Rostock, Rostock, Germany.

Eileen Moritz (E)

Institute of Pharmacology, Department of General Pharmacology, University Medicine Greifswald, Greifswald, Germany.

Maria Geffken (M)

Institute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Joerg Schreiber (J)

Center for Anesthesiology, Intensive Care Medicine, Pain Therapy and Palliative Medicine, Benedictus Krankenhaus Tutzing, Tutzing, Germany.

Gillis Greiwe (G)

Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Katharina Amschler (K)

Department of Allergology and Venerology, University Medicine Göttingen, Göttingen, Germany.

Marie-Louise Wruck (ML)

Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Edzard Schwedhelm (E)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Günter Daum (G)

Clinic and Policlinic for Vascular Medicine, University Heart Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Stefan Kluge (S)

Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Sven Peine (S)

Institute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Martin Sebastian Winkler (MS)

Center for Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Anesthesiology and Intensive Care Medicine, University Medicine Göttingen, Göttingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH